Last reviewed · How we verify
Amylin
At a glance
| Generic name | Amylin |
|---|---|
| Sponsor | Danish Headache Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities (PHASE2)
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (PHASE3)
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (PHASE2)
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (PHASE1)
- A Causative Role for Amylin in Diabetic Peripheral Neuropathy
- A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295 (PHASE1)
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) (PHASE2)
- Amylin-Induced Migraine Attacks Without Aura (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |